Janus Kinase Inhibitors for Alopecia Areata

    August 2023 in “ Journal of the American Academy of Dermatology ”
    Brett King, Brittany G. Craiglow
    Studysummary This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    2. Utility of Azathioprine, Methotrexate, and Cyclosporine as Steroid-Sparing Agents in Chronic Alopecia Areata: A Retrospective Study of Continuation Rates in 138 Patients JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2020
    3. Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata Journal of The American Academy of Dermatology · 2019
    4. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    5. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    6. Lymphocytes, Neuropeptides, And Genes Involved In Alopecia Areata Journal of Clinical Investigation · 2007

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019